- Home
- PCRX vs ORIC Comparison
PCRX vs ORIC Comparison
Compare PCRX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ORIC
- Stock Information
- Founded
- PCRX 2006
- ORIC 2014
- Country
- PCRX United States
- ORIC United States
- Employees
- PCRX N/A
- ORIC N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- ORIC Health Care
- Exchange
- PCRX Nasdaq
- ORIC Nasdaq
- Market Cap
- PCRX 1.2B
- ORIC 362.9M
- IPO Year
- PCRX 2011
- ORIC 2020
- Fundamental
- Price
- PCRX $22.90
- ORIC $11.10
- Analyst Decision
- PCRX Buy
- ORIC Strong Buy
- Analyst Count
- PCRX 8
- ORIC 9
- Target Price
- PCRX $28.38
- ORIC $18.29
- AVG Volume (30 Days)
- PCRX 545.0K
- ORIC 949.2K
- Earning Date
- PCRX 07-29-2025
- ORIC 08-11-2025
- Dividend Yield
- PCRX N/A
- ORIC N/A
- EPS Growth
- PCRX N/A
- ORIC N/A
- EPS
- PCRX N/A
- ORIC N/A
- Revenue
- PCRX $702,772,000.00
- ORIC N/A
- Revenue This Year
- PCRX $7.54
- ORIC N/A
- Revenue Next Year
- PCRX $10.78
- ORIC N/A
- P/E Ratio
- PCRX N/A
- ORIC N/A
- Revenue Growth
- PCRX 3.08
- ORIC N/A
- 52 Week Low
- PCRX $11.16
- ORIC $3.90
- 52 Week High
- PCRX $27.64
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- ORIC 66.82
- Support Level
- PCRX $22.82
- ORIC $10.42
- Resistance Level
- PCRX $23.83
- ORIC $11.50
- Average True Range (ATR)
- PCRX 0.74
- ORIC 0.62
- MACD
- PCRX -0.02
- ORIC -0.03
- Stochastic Oscillator
- PCRX 6.22
- ORIC 83.30
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.